



Mononuclear Cell Collection

Amicus Separator

Therapeutic Apheresis and Cell Therapy

The Amicus Separator device to perform automated, mononuclear cell collection (MNC) with high yields and low patient platelet loss.^{1,2}

High MNC collection efficiency with low platelet loss

Flexible controls allow tailoring of MNC settings for target cell content based upon clinical need

Automated custom prime for lower blood volume and lower hematocrit patients

Low extracorporeal volume (163 mL)

Putting precision collection at your fingertips

80%


Median
MNC Collection
Efficiency (CE1)

Optimize collection efficiencies

Meeting your patients' clinical needs is always your primary goal. The Amicus design delivers precision with the high efficiency you've come to expect.

HIGH COLLECTION EFFICIENCIES

	Auto ^{1*} (mobilized)	Allo ^{1*} (mobilized)	Allo ² (non-mobilized)
MNC CE1 % (median)	80 (n=87)	70 (n=17)	
MNC CE2 % (median)	60 (n=75)		
CD34+ CE1 % (median)	66 (n=85)	82 (n=18)	CD34+ CE1 % (mean ± SD) 64 ± 15 (n=12)



Longer MNC harvest can be achieved by increasing the RBC Offset to fully capture the MNCs.

Tailor collections

Every MNC collection is different because every patient and donor is different. Amicus is designed to make it easy to tailor collections for high product purity and high MNC yield.

HIGH PRODUCT PURITY


	Auto ^{1*} (mobilized)	Allo ^{1*} (mobilized)	Allo ² (non-mobilized)
Platelets x 10¹¹ (median)	0.43 (n=97)	0.57 (n=18)	Platelets x 10¹¹ (mean ± SD) 0.46 ± 14.7 (n=12)
Granulocytes % (median)	33 (n=97)	14 (n=19)	
Red Cell Hct % (median)	13.6 (n=62)	3.8 (n=14)	Red Cell Hct % (mean ± SD) 9.6 ± 2.6 (n=12)
Product Volume (mL) (median)	176 (n=97)	160 (n=18)	Product Volume (mL) (mean ± SD) 50.4 ± 3.5 (n=12)

* Mobilization with G-CSF + chemotherapy for patients and G-CSF alone for healthy subjects per institutional practice.

Providing safe care to patients and donors

10% Median Platelet Loss

← Platelets return during collection



With Amicus, whole blood enters the centrifuge chamber and begins to separate, as the separation interface is established platelet rich plasma is returned to the patient.

Spare platelets

One therapeutic procedure shouldn't result in the need for another one. Amicus keeps median platelet loss at 10%¹, so you can perform MNC procedures on patients and donors with reduced need of associated platelet transfusion.^{3,4}

LOW PLATELET LOSS

	Auto ¹ (mobilized)	Allo ¹ (mobilized)		Allo ² (non-mobilized)
Platelet loss % (median)	10 (n=95)	7 (n=18)	Platelet loss % (mean ± SD)	2.3 ± 4.7 (n=12)
Platelet CE1 % (median)	4 (n=94)	4 (n=19)	Platelet CE1 % (mean ± SD)	3.6 ± 1.3 (n=12)

163mL Extracorporeal Kit Volume

Support patient comfort

Comfort is a key part of the care you provide. With low extracorporeal volume (ECV) and low-noise operation, Amicus delivers a gentle experience, even for delicate patients and donors.

Source

¹ FCRP-0297: Investigational Plan for the Harvesting of PBSC in G-CSF and Chemotherapy Mobilized Patients using Amicus Separator, December, 2000 and Post Hoc Analysis for FCRP-0297, March, 2014. Data on file.

² Steininger PA, Strasser EF, Weiss D, Achenbach S, Zimmerman R, Ekstein R. First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors. Vox Sanguinis 2013; DOI 10.1111/vox. 12102

³ Ikeda K, Ohto H, Kanno, T, Ogata T, Noji H, Ogawa K, Maruyama Y. Automated programs for collection of mononuclear cells and progenitor cells by two separators for peripheral blood progenitor cell transplantation: comparison by a randomized crossover study. Transfusion. 2007 Jul;47:1234-1240.

⁴ Ikeda K, et al. Collection of MNCs and progenitor cells by two separators for PBPC transplantation: a randomized crossover trial. Transfusion. 2003 Jun;43:814-819.

Mononuclear Cell Collection

MNC collection focused on your patients' care

Automated custom prime

In situations with patients that have a lower total blood volume or lower hematocrit, Amicus offers a custom prime option that allows customization of settings to trigger an option to use an alternate fluid for priming the kit. Helps ensure patient remains isovolemic at the start of the procedure.

Sterilization using irradiation

Sterilization of apheresis kits with irradiation avoids the risk of reactions related to patient exposure to residual ethylene oxide and eliminates the need for double priming the kit.

Precision design to help you achieve more

This marking reflects compliance with the applicable CE Marking requirements for medical devices.



Refer to Amicus Operator's Manual for a full list of warnings and cautions associated with the use of the Amicus device.



Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany

Phone: +49 61 72 608-0

Corporate
www.fresenius-kabi.com

Amicus Blue Therapeutics
www.amicusblue-fresenius-kabi.com
amicus@fresenius-kabi.com